Form 4: Vaxcyte COO Jim Wassil Reports Share Dispositions

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of 4,422 shares of common stock through tax withholding and a divorce settlement.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reported changes in his beneficial ownership of Vaxcyte common stock.
• On September 8, 2025, Wassil disposed of 2,759 shares of common stock at a price of $32.41 per share. These shares were surrendered to Vaxcyte to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• On September 9, 2025, Wassil transferred an additional 1,663 shares of Vaxcyte, Inc. Common Stock to his ex-spouse as part of a divorce settlement agreement, pursuant to a domestic relations order.
• Following these transactions, Jim Wassil beneficially owns 141,848 shares of Vaxcyte, Inc. Common Stock.

Sentiment

Score: 5

Explanation: Neutral. The transactions are routine for an executive's equity compensation and personal financial matters, not reflecting positively or negatively on the company's operational performance or future prospects.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects personal financial management of an executive's equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine personal transactions by an executive, not indicative of company performance or strategic shifts.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to tax withholding on RSU vesting and a personal divorce settlement. These events are not indicative of Vaxcyte's operational performance, financial health, or strategic direction. As such, they do not provide a basis for a change in investment recommendation. Investors should continue to hold based on fundamental analysis of the company's business, pipeline, and market position, rather than these personal dispositions.

Keywords

Vaxcyte, PCVX, Jim Wassil, Chief Operating Officer, Insider Transaction, Form 4, Share Disposition, Tax Withholding, Divorce Settlement, Beneficial Ownership